Gilead Sciences, Inc Sample Clauses

Gilead Sciences, Inc. Gilead has retained exclusive rights in the Patents identified by a "Gilead" in the Third Party column to make, have made, use, import, export or sell compounds and other subject matter claimed within the scope of the patents which are [**]. In addition, Gilead has a non-exclusive, non-sublicensable, non-assignable license under such Patents to make and use CodeBlocker Compounds and Oligonucleotide Delivery Systems for internal research purposes, but not for any commercial purpose.
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
Gilead Sciences, Inc. | Ci ty o f Fo s te r Ci ty , CA A five story H and B occupancy biotech building project included challenging occupancy separations as well as adverse soil conditions. Santa Xxxx Warriors Arena | C i ty o f Sa n ta Cr u z , CA New 3,000 seat basketball arena with associated restrooms, locker rooms and concessions. Palo Alto History Museum | C i ty o f P a lo A l to , CA This project involved the extensive remodel of historic building to house history museum and archive. Revised usage required careful study of exiting systems. This project utilized CBHC provisions for accessibility. Ocean Street Commons | C i ty o f Sa n ta Cr u z , CA This project consisted of 9 residential units over commercial space and was wood framed construction. Additional projects included multiple tenant improvement projects of varying sizes as well as multiple new and additions to single-family homes. JURISDICTIONAL EXPERIENCE Residential / Commercial Building Inspector Towns/Cities of Atherton, Brisbane, Half Moon Bay, Los Altos Hills, Pacifica, Sausalito, Monte Sereno, and SLAC Linear Accelerator Laboratory In-House Plan Review Towns/Cities of Atherton, Santa Cruz, Salinas, San Xxxx, and SLAC National Accelerator Laboratory Over the Counter Plan Review Towns/Cities of Atherton, Belmont, Pacifica, Santa Xxxx, Sausalito, Woodside Building Official / Interim Building Official Towns/Cities of Woodside (BO), Xxxxxxxx (Interim BO), Pacifica (interim BO) Xxxx LICENSES and CERTIFICATIONS DSA Certified Access Specialist (CASp) | 071 Master Code Professional 5230795-MP Certified Building Official 5230795-CB Building Plans Examiner 5230795-B3 Residential Plans Examiner 5230795-R3 Building Inspector, UBC 5230795-10 Plans Examiner, UBC 5230795-60 Plumbing Inspector, UPC 5230795-34 Mechanical Inspector UMC 5230795-44 Residential Electrical Inspector 5230795-E1 Commercial Electrical Inspector 5230795-E2 Combination Inspector Uniform Codes | 5230795-50 Residential Energy Inspector/ Plans Examination | 5230795-79 Commercial Energy Plans Examination | 5230795-78 Commercial Energy Inspector | 5230795-77 Accessibility Inspector/ Plans Examiner | 5230795-21 Building Inspector | 5230795-B5 Combination Inspector | 5230795-C8 Residential Combination Inspector | 5230795-R5 Fire Inspector 1 | 5230795-66 Safety Assessment Program | XXXX00000 FEMA IS-00700 National Incident Management Systems | 6-1-06 IACET First Responder Awareness | 66448 (Association of Bay Area Governments) California State Contractors...
Sample 1
Gilead Sciences, Inc. No. 20-CIV-03699 (Cal. Sup. Ct., San Mateo Cty.) (or substantially similar clear and unambiguous language), no later than sixty (60) days after the Notice of Settlement is sent to Settlement Class Members by the Settlement Administrator (the “Opt-Out Date”). That written request shall contain the Settlement Class Member’s printed name, address, telephone number, email address, and date of birth. A written request for exclusion must contain the actual written signature of the Settlement Class Member seeking to exclude himself or herself from the Settlement Class and requests for exclusion cannot be made on a group or class basis. The Settlement Administrator will provide redacted and de-identified copies of all requests for exclusion to Co-Lead Class Counsel and Counsel for Gilead as they are received, and only redacted and de-identified copies shall be filed with the Court. All Settlement Class Members who do not timely and properly request exclusion from the Settlement Class will in all respects be bound by all terms of this Settlement Agreement and the Court’s Final Approval Order, and upon the Effective Date, will be entitled to all benefits described in this Settlement Agreement. Settlement Class Members who opt out can withdraw their request for exclusion before the Final Approval Hearing by submitting a written request stating their desire to revoke their request for exclusion along with their written signature. In the event that more than one percent (1%) of the Settlement Class Members timely and validly opt out, Gilead may, by notifying Co-Lead Class Counsel and the Court in writing within ten (10) days of the Opt-Out deadline, void this Settlement Agreement, in which case the Parties shall return to their respective positions before this Agreement was executed.
Sample 1
Gilead Sciences, Inc a Delaware Corporation (“Gilead Sciences” and, together with Gilead Sciences Ireland, “Gilead”);
Sample 1
Gilead Sciences, Inc a corporation existing under the laws of Delaware (the “Parent”) - and - 3268218 NOVA SCOTIA LIMITED, a company incorporated under the laws of the Province of Nova Scotia (the “Purchaser”) - and - YM BIOSCIENCES INC., a company continued under the laws of the Province of Nova Scotia (the “Company”)
Sample 1
Gilead Sciences, Inc a Delaware corporation having its principal place of business at 000 Xxxxxxxx Xxxxx, Xxxxxx Xxxx, XX, 00000, Xxxxxx Xxxxxx of America (hereinafter referred to as the “Parent Investor”) Issuer and Investor are hereinafter individually referred to as “Party” and collectively as “Parties”.
Sample 1

Related to Gilead Sciences, Inc

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Manufacturing Agreement Each of the Sellers (as applicable) shall have executed and delivered to the Buyer the Manufacturing Agreement with respect to the portion of the Business conducted at the applicable Facility.

  • License Agreement The Trust shall have the non-exclusive right to use the name "Invesco" to designate any current or future series of shares only so long as Invesco Advisers, Inc. serves as investment manager or adviser to the Trust with respect to such series of shares.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

Time is Money Join Law Insider Premium to draft better contracts faster.